Recruiting now—All ages

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Sponsor: Pell Bio-Med Technology Co., Ltd. · NCT05377307 on ClinicalTrials.gov ↗

Conditions studied

Diffuse Large B Cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell LymphomaFollicular Lymphoma Grade 3AFollicular Lymphoma Grade 3B

What it tests

Pell's lentiviral-based gene-edited immune cell therapygenetic

Where it's running5 sites

5 international sites

Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, Taiwan 807377
Recruiting now
- Yi-Chang Liu(principal investigator)
National Taiwan University Hospital
Taipei, Taiwan, Taiwan 10025
Recruiting now
- Shang-Ju Wu(principal investigator)
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan 112201
Recruiting now
- Jyh-Pyng Gau(principal investigator)
Chi Mei Medical Center
Tainan, Taiwan 710
Recruiting now
- Hung-Chang Wu(principal investigator)
Taipei Medical University - Taipei Medical University Hospital
Taipei, Taiwan 11031
Recruiting now
- Chao-Hua Chiu(contact)

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

1. Patients must have ever received Pell's lentiviral-based gene-edited immune cell as monotherapy or as combination therapy in clinical trials.
2. The last lentiviral-based gene-edited immune cell infusion within 15 years.
3. Patient/patient's parent/legal guardian is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

There are no specific exclusion criteria for this study.

Updated 2025-05-13 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.